Lysophosphatidylcholine upregulates LOX-1, chemokine receptors, and activation-related transcription factors in human T-cell line Jurkat

Journal of Thrombosis and Thrombolysis

Volumn 26, Issue 2, 2008, Pages 113-118

  Hara, Yuko ^a,b,c   Kusumi, Yoshiaki ^b   Mitsumata, Masako ^b   Li, Xiao Kang ^c   Fujino, Masayuki ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Arteriosclerosis; CD4T cell; Chemokine receptor; LOX 1; Lysophosphatidylcholine; Real time RT PCR

Indexed keywords

BCL2 RELATED PROTEIN A1; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YY1;

ARTICLE; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREGULATION; LEUKEMIA CELL LINE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ATHEROSCLEROSIS; CELL PROLIFERATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; JURKAT CELLS; LYSOPHOSPHATIDYLCHOLINES; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS E; T-LYMPHOCYTES; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; YY1 TRANSCRIPTION FACTOR;

EID: 56049125698     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0158-x     Document Type: Article

References (34)

1. Powrie F, Coffman RL (1993) Cytokine regulation of T-cell function: potential for therapeutic intervention. Immunol Today 14:270-274
2. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK (1995) T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92:3893-3897
3. Hancock WW, Adams DH, Wyner LR, Sayegh MH, Karnovsky MJ (1994) CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury. Am J Pathol 145:1008-1014
4. Emeson EE, Shen ML, Bell CG, Qureshi A (1996) Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol 149:675-685
5. Russell ME, Hancock WW, Akalin E et al (1996) Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 97:833-838
6. Hansson GK, Jonasson L, Seifert PS, Stemme S (1989) Immune mechanisms in atherosclerosis. Arteriosclerosis 9:567-578
7. Stemme S, Holm J, Hansson GK (1992) T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 12:206-211
8. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924
9. Sakai M, Miyazaki A, Hakamata H et al (1994) Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J Biol Chem 269:31430-31435
10. Han KH, Hong KH, Ko J et al (2004) Lysophosphatidylcholine up-regulates CXCR4 chemokine receptor expression in human CD4 T cells. J Leukoc Biol 76:195-202. Epub 2004 Jun 2003
11. Higuchi R, Fockler C, Dollinger G, Watson R (1993) Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (NY) 11:1026-1030
12. Engeli S, Bohnke J, Feldpausch M et al (2004) Regulation of 11beta-HSD genes in human adipose tissue: Influence of central obesity and weight loss. Obes Res 12:9-17
13. Smirnova IV, Kajstura M, Sawamura T, Goligorsky MS (2004) Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: Role in foam cell formation. Am J Physiol Heart Circ Physiol 287:H782-H790. Epub 2004 Mar 2011
14. Aoki J, Taira A, Takanezawa Y et al (2002) Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 277:48737-48744. Epub 42002 Sep 48726
15. Steinbrecher UP, Zhang HF, Lougheed M (1990) Role of oxidatively modified LDL in atherosclerosis. Free Radic Biol Med 9:155-168
16. Noguchi N (2002) Novel insights into the molecular mechanisms of the antiatherosclerotic properties of antioxidants: The alternatives to radical scavenging. Free Radic Biol Med 33:1480-1489
17. van der Wal AC, Becker AE (1999) Atherosclerotic plaque rupture - pathologic basis of plaque stability and instability. Cardiovasc Res 41:334-344
18. de Boer OJ, van der Wal AC, Houtkamp MA, Ossewaarde JM, Teeling P, Becker AE (2000) Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. Cardiovasc Res 48:402-408
19. Frostegard J, Ulfgren AK, Nyberg P et al (1999) Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145:33-43
20. Aoyama T, Chen M, Fujiwara H, Masaki T, Sawamura T (2000) LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett 467:217-220
21. Fei GZ, Huang YH, Swedenborg J, Frostegard J (2003) Oxidised LDL modulates immune-activation by an IL-12 dependent mechanism. Atherosclerosis 169:77-85
22. Maziere C, Morliere P, Massy Z et al (2005) Oxidized low-density lipoprotein elicits an intracellular calcium rise and increases the binding activity of the transcription factor NFAT. Free Radic Biol Med 38:472-480
23. Masamune A, Sakai Y, Yoshida M, Satoh A, Satoh K, Shimosegawa T (2001) Lysophosphatidylcholine activates transcription factor NF-kappaB and AP-1 in AR42J cells. Dig Dis Sci 46:1871-1881
24. Ryborg AK, Johansen C, Iversen L, Kragballe K (2004) Lysophosphatidylcholine induces keratinocyte differentiation and upregulation of AP-1- and NF-kappaB DNA-binding activity. Acta Derm Venereol 84:433-438
25. Yang CH, Fang IM, Lin CP, Yang CM, Chen MS (2005) Effects of the NF-kappaB inhibitor pyrrolidine dithiocarbamate on experimentally induced autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 46:1339-1347
26. Li L, Sawamura T, Renier G (2004) Glucose enhances human macrophage LOX-1 expression: Role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res 94:892-901. Epub 2004 Mar 2004
27. Pikarsky E, Porat RM, Stein I et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466. Epub 2004 Aug 2025
28. Sui G, Affar el B, Shi Y et al (2004) Yin Yang 1 is a negative regulator of p53. Cell 117:859-872
29. Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B (2005) Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 24:8114-8127
30. Kabelitz D, Pohl T, Pechhold K (1993) Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 14:338-339
31. Legradi A, Chitu V, Szukacsov V, Fajka-Boja R, Szekely Szucs K, Monostori E (2004) Lysophosphatidylcholine is a regulator of tyrosine kinase activity and intracellular Ca(2+) level in Jurkat T cell line. Immunol Lett 91:17-21
32. Lewis RS (2001) Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol 19:497-521
33. Asaoka Y, Oka M, Yoshida K, Sasaki Y, Nishizuka Y (1992) Role of lysophosphatidylcholine in T-lymphocyte activation: Involvement of phospholipase A2 in signal transduction through protein kinase C. Proc Natl Acad Sci USA 89:6447-6451
34. Ventura C, Maioli M (2001) Protein kinase C control of gene expression. Crit Rev Eukaryot Gene Expr 11:243-267